## ADDENDUM TO CLINICAL REVIEW

Application Type NDA
Application Number(s) 22-502
Priority or Standard Standard

Submit Date(s) February 27, 2009 Received Date(s) March 2, 2009 PDUFA Goal Date January 2, 2010

Reviewer Name(s) Amy Woitach, D.O. Review Completion Date March 2, 2010

Established Name Adapalene Lotion, 0.1%
(Proposed) Trade Name Differin Lotion, 0.1%
Therapeutic Class Naphthoic acid/ Retinoid
Applicant Galderma Laboratories LP


Formulation(s) Topical lotion
Dosing Regimen Once daily
Indication(s) Acne vulgaris
Intended Population(s) 12 years and older


Galderma submitted an original NDA on March 2, 2009 for Differin (adapalene) Lotion 0.1% for the treatment of acne vulgaris. The clinical review was closed on November 12, 2009. Inspections of manufacturing facilities were pending at the time of the close of the review. Labeling negotiations were also ongoing.

Inspections	of Ma	nufact	urina	Fooil	itioa.
mspections	OI IVI	เมนาละเ	urme	гасп	nues.

On December 18, 2009 the Office of Compliance issued an overall recommendation of "withhold" based on the inspection of the determined the facility was not ready for inspection. The sponsor was notified of the recommendation to withhold the approval by teleconference on December 22, 2009. On December 23, 2009 the sponsor submitted an amendment to remove the facility from the application. The amendment is considered a major amendment and extends the review clock by 3 months with a new PDUFA date of April 2, 2009. Based on the amendment, the Office of Compliance has issued a recommendation of "acceptable" on January 14, 2010.

## <u>Labeling Negotiations</u>:





(b) (4)

The Agency initiated a second teleconference in which the sponsor confirmed that clinical trials were conducted with the pump inserted into the bottle prior to dispensing to subjects.

The Agency requested that the sponsor submit color mock ups of carton and container labels and provide instructions to the pharmacist; Galderma submitted this information in amendment on December 1, 2009.

DMEPA reviewer Lori Cantin provided draft comments to the Division stating that labeling is not likely to prevent the dispensing of the configuration.

Reviewer comment: This reviewer recommends approving the assembled configuration, with the pump inserted into the bottle, so that the configuration and dosing is consistent with that used in the phase 3 trials.

The Agency initiated a teleconference on January 28, 2010 to inform the applicant that the

With the Office of Compliance issuing an overall recommendation of "acceptable" and the resolution of labeling issues the CMC reviewer is recommending approval of this NDA.

Reviewer comment: This reviewer concurs and recommends approval of the NDA.

Labeling negotiations are complete. The revised carton and container labeling was deemed acceptable. The agreed upon label is appended to this review.

10 Page of Draft Labeling as been withheld in full after this page as B4 (CCI/TS)

Application Type/Number	Submission Type/Number	Submitter Name	Product Name	
NDA-22502	ORIG-1	GALDERMA RESEARCH AND DEVELOPMENT INC		
•		electronic records the manifestatio	I that was signed on of the electronic	
/s/				
AMY S WOITACH 03/03/2010	1			
DAVID L KETTL 03/03/2010				

Concur with approval recommendation as CMC issues have been resolved.